The Role of p53 on Survival of Upper Urinary Tract Urothelial Carcinoma: A Systematic Review and Meta-Analysis

Jemal, 2005, Cancer statistics, 2005, CA Cancer J Clin, 55, 10, 10.3322/canjclin.55.1.10

Raman, 2011, Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005, BJU Int, 107, 1059, 10.1111/j.1464-410X.2010.09675.x

Lughezzani, 2012, Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature, Eur Urol, 62, 100, 10.1016/j.eururo.2012.02.030

Shariat, 2008, Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy, Cancer, 112, 315, 10.1002/cncr.23162

Schmitz-Dräger, 2000, p53 immunohistochemistry as a prognostic marker in bladder cancer, Eur Urol, 38, 691, 10.1159/000020364

Malats, 2005, P53 as a prognostic marker for bladder cancer: a meta-analysis and review, Lancet Oncol, 6, 678, 10.1016/S1470-2045(05)70315-6

Stadler, 2011, Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status, J Clin Oncol, 29, 3443, 10.1200/JCO.2010.34.4028

Mitchell, 2011, Expression of p53 in upper urinary tract urothelial carcinoma, Nat Rev Urol, 8, 516, 10.1038/nrurol.2011.92

Altman, 2005, Primer: an evidence-based approach to prognostic markers, Nat Clin Pract Oncol, 2, 466, 10.1038/ncponc0287

de Graeff, 2009, Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis, Br J Cancer, 101, 149, 10.1038/sj.bjc.6605112

Hayes, 1996, Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers, J Natl Cancer Inst, 88, 1456, 10.1093/jnci/88.20.1456

McShane, 2005, REporting recommendations for tumour MARKer prognostic studies (REMARK), Br J Cancer, 93, 387, 10.1038/sj.bjc.6602678

Parmar, 1998, Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints, Stat Med, 17, 2815, 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8

Williamson, 2002, Aggregate data meta-analysis with time-to-event outcomes, Stat Med, 21, 3337, 10.1002/sim.1303

Tierney, 2007, Practical methods for incorporating summary time-to-event data into meta-analysis, Trials, 8, 16, 10.1186/1745-6215-8-16

DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2

Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557

Nakanishi, 1998, Expression of bcl-2 oncoprotein in transitional cell carcinoma of the upper urinary tract, Virchows Arch, 432qj, 445, 10.1007/s004280050189

Nakanishi, 1999, Expression of telomerase mRNA component (hTR) in transitional cell carcinoma of the upper urinary tract, Cancer, 86, 2109, 10.1002/(SICI)1097-0142(19991115)86:10<2109::AID-CNCR32>3.0.CO;2-6

Nakanishi, 2002, Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract, Virchows Arch, 441, 559, 10.1007/s00428-002-0712-z

Nakanishi, 2005, Expression of hypoxia-inducible factor-1alpha protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract, Clin Cancer Res, 11, 2583, 10.1158/1078-0432.CCR-04-1685

Bringuier, 1998, Carcinomas of the renal pelvis associated with smoking and phenacetin abuse: p53 mutations and polymorphism of carcinogen-metabolising enzymes, Int J Cancer, 79, 531, 10.1002/(SICI)1097-0215(19981023)79:5<531::AID-IJC15>3.0.CO;2-4

Watanabe, 2005, Clinical evaluation of serum p53 antibodies in patients with upper urinary tract tumors, J Urol, 174, 73, 10.1097/01.ju.0000162053.44205.6e

Izquierdo, 2010, Molecular characterization of upper urinary tract tumours, BJU Int, 106, 868, 10.1111/j.1464-410X.2009.09135.x

Hashimoto, 2000, Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter, Int J Urol, 7, 457, 10.1046/j.1442-2042.2000.00230.x

Kamijima, 2005, The prognostic value of p53, Ki-67 and matrix metalloproteinases MMP-2 and MMP-9 in transitional cell carcinoma of the renal pelvis and ureter, Int J Urol, 12, 941, 10.1111/j.1442-2042.2005.01159.x

Jeong, 2009, Prognostic value of apoptosis-related markers in urothelial cancer of the upper urinary tract, Hum Pathol, 40, 668, 10.1016/j.humpath.2008.10.010

Furihata, 1998, Prognostic significance of cyclin E and p53 protein overexpression in carcinoma of the renal pelvis and ureter, Br J Cancer, 77, 783, 10.1038/bjc.1998.127

Okamura, 1996, Immunohistochemical evaluation of p53 and retinoblastoma proteins in relation to hyperthermia treatment: results in human urothelial carcinomas, Int J Hyperthermia, 12, 813, 10.3109/02656739609027687

Terrell, 1995, Histopathological features and p53 nuclear protein staining as predictors of survival and tumor recurrence in patients with transitional cell carcinoma of the renal pelvis, J Urol, 154, 1342, 10.1016/S0022-5347(01)66855-1

Nakanishi, 1996, Immunohistochemical evaluation of p53 oncoprotein in transitional cell carcinoma of the upper urinary tract, Hum Pathol, 27, 1336, 10.1016/S0046-8177(96)90347-0

Rey, 1997, Overexpression of p53 in transitional cell carcinoma of the renal pelvis and ureter, Cancer, 79, 2178, 10.1002/(SICI)1097-0142(19970601)79:11<2178::AID-CNCR16>3.0.CO;2-T

Jinza, 1998, Prognostic significance of p53 protein overexpression in transitional cell carcinoma of the renal pelvis and ureter, Urol Int, 60, 147, 10.1159/000030239

Zigeuner, 2004, Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma, Urology, 63, 1079, 10.1016/j.urology.2004.01.009

Fromont, 2005, Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma, Eur Urol, 48, 764, 10.1016/j.eururo.2005.07.005

Scarpini, 2012, Impact of the expression of Aurora-A, p53, and MIB-1 on the prognosis of urothelial carcinomas of the upper urinary tract, Urol Oncol, 30, 182, 10.1016/j.urolonc.2009.12.003

Hainaut, 2000, p53 and human cancer: the first ten thousand mutations, Adv Cancer Res, 77, 81, 10.1016/S0065-230X(08)60785-X

Hollstein, 1991, p53 mutations in human cancers, Science, 253, 49, 10.1126/science.1905840

Wynford-Thomas, 1992, P53 in tumour pathology: can we trust immunocytochemistry?, J Pathol, 166, 329, 10.1002/path.1711660402

Levidou, 2010, P53 immunoexpression as a prognostic marker for human astrocytomas: a meta-analysis and review of the literature, J Neuroncol, 100, 363, 10.1007/s11060-010-0204-y

Wolff, 1994, Retinoblastoma and p53 genes as prognostic indicators in urological oncology, Urol Int, 53, 1, 10.1159/000282622

Lipponen, 1993, Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value, Int J Cancer, 53, 365, 10.1002/ijc.2910530304

Esrig, 1993, p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer, Am J Pathol, 143

Stewart, 1993, Meta-analysis of the literature or of individual patient data: is there a difference?, Lancet, 341, 418, 10.1016/0140-6736(93)93004-K

Altman, 1994, Dangers of using ‘optimal’ cutpoints in the evaluation of prognostic factors, J Natl Cancer Inst, 86, 829, 10.1093/jnci/86.11.829

Egger, 1997, Language bias in randomised controlled trials published in English and German, Lancet, 350, 326, 10.1016/S0140-6736(97)02419-7

Hayes, 2001, Prognostic factors in breast cancer: current and new predictors of metastasis, J Mammary Gland Biol Neoplasia, 6, 375, 10.1023/A:1014778713034

Shariat, 2007, Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder, Urol Oncol, 25, 468, 10.1016/j.urolonc.2006.09.011

Als, 2007, Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer, Clin Cancer Res, 13, 4407, 10.1158/1078-0432.CCR-07-0109

Karam, 2007, Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy, Lancet Oncol, 8, 128, 10.1016/S1470-2045(07)70002-5